As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...
iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...
Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance ...
iPSCore platform delivered over 500 characterized iPSC lines during first year of collaboration SAN DIEGO, March 11, 2026--(BUSINESS WIRE)--iXCells Biotechnologies USA, Inc. ("iXCells"), a leading ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results